0001209191-20-025028.txt : 20200417
0001209191-20-025028.hdr.sgml : 20200417
20200417214837
ACCESSION NUMBER: 0001209191-20-025028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200415
FILED AS OF DATE: 20200417
DATE AS OF CHANGE: 20200417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENEVICH ERIC
CENTRAL INDEX KEY: 0001643653
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 20801125
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-15
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001643653
BENEVICH ERIC
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Commercial Officer
Common Stock
2020-04-15
4
S
0
8632
94.6499
D
11603
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $92.80 to $95.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Includes 148 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020.
/s/ Darin Lippoldt, Attorney-in-Fact
2020-04-17